Franklin Street Advisors Inc. NC cut its holdings in Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) by 29.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,430 shares of the specialty pharmaceutical company’s stock after selling 1,000 shares during the quarter. Franklin Street Advisors Inc. NC’s holdings in Jazz Pharmaceuticals were worth $327,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also modified their holdings of JAZZ. Dimensional Fund Advisors LP raised its position in shares of Jazz Pharmaceuticals by 49.1% during the second quarter. Dimensional Fund Advisors LP now owns 229,898 shares of the specialty pharmaceutical company’s stock worth $35,750,000 after purchasing an additional 75,703 shares during the period. Summit Partners Public Asset Management LLC acquired a new position in shares of Jazz Pharmaceuticals during the second quarter worth approximately $10,108,000. AXA raised its position in shares of Jazz Pharmaceuticals by 23.2% during the third quarter. AXA now owns 116,862 shares of the specialty pharmaceutical company’s stock worth $17,091,000 after purchasing an additional 22,007 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in shares of Jazz Pharmaceuticals during the third quarter worth approximately $296,000. Finally, Schroder Investment Management Group acquired a new position in shares of Jazz Pharmaceuticals during the third quarter worth approximately $52,571,000. 91.36% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Jazz Pharmaceuticals plc – (NASDAQ JAZZ) traded down $2.52 during trading on Friday, reaching $143.83. The company had a trading volume of 343,788 shares, compared to its average volume of 454,985. The company has a market capitalization of $8,770.00, a P/E ratio of 23.70, a P/E/G ratio of 0.77 and a beta of 0.99. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.10 and a quick ratio of 2.94. Jazz Pharmaceuticals plc – has a 1-year low of $121.71 and a 1-year high of $163.75.
A number of equities analysts have recently weighed in on JAZZ shares. FBR & Co started coverage on Jazz Pharmaceuticals in a research report on Thursday, October 19th. They set a “buy” rating and a $206.00 target price on the stock. Royal Bank of Canada lowered their target price on Jazz Pharmaceuticals from $210.00 to $195.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 8th. Leerink Swann started coverage on Jazz Pharmaceuticals in a research report on Tuesday, January 2nd. They set an “outperform” rating and a $180.00 target price on the stock. Zacks Investment Research raised Jazz Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, January 12th. Finally, Cowen set a $190.00 target price on Jazz Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, October 23rd. One research analyst has rated the stock with a sell rating, six have given a hold rating and seventeen have assigned a buy rating to the company’s stock. Jazz Pharmaceuticals has an average rating of “Buy” and an average price target of $179.44.
In other Jazz Pharmaceuticals news, CFO Matthew P. Young sold 700 shares of the company’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $152.16, for a total value of $106,512.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bruce C. Cozadd sold 3,000 shares of the company’s stock in a transaction on Friday, January 12th. The shares were sold at an average price of $150.00, for a total value of $450,000.00. The disclosure for this sale can be found here. Insiders sold a total of 21,452 shares of company stock valued at $2,985,885 in the last 90 days. Corporate insiders own 4.30% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was originally posted by BBNS and is the sole property of of BBNS. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://baseballnewssource.com/2018/02/02/jazz-pharmaceuticals-plc-jazz-position-trimmed-by-franklin-street-advisors-inc-nc/1824719.html.
Jazz Pharmaceuticals Profile
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.